Beyond Prognosis: How Studying Cancer Overachievers Can Redefine the Future of Oncology Innovation

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio

Cancer care is traditionally designed around the typical median patient, which means innovation is often incremental, predictable, and slow. Yet within every cancer type, a small group of patients achieves what medicine still cannot fully explain: survival far beyond statistical history and expectations. These “cancer outliers” aren’t anomalies – they are biological outcomes. They show us what is possible when human resilience, genetics, immunity, and environment align in extraordinary ways.

Until recently, studying them at scale was impossible. Data was siloed, cohorts were tiny, and research units weren’t built for outlier science. Studying unique survivors systematically wasn’t feasible.  And most importantly, there was no infrastructure to centralise and analyse these unique trajectories.

Data science, AI, global consent frameworks, and digital biobanking are enabling something that used to be scientifically impossible: the ability to study cancer resilience at scale. At Cure51, we are building the world’s first global database dedicated to identifying, characterising, and understanding these “Outliers” – patients whose biology shows us what might be universally achievable tomorrow. But this emerging field is bigger than one initiative. A new ecosystem is coming into view, and it sits squarely at the intersection of oncology and deep tech.

For startups, this represents one of the most overlooked white spaces in health innovation. The potential impact spans far beyond explaining why certain patients do unusually well. By decoding common resilience patterns – immune signatures, genetic variants, metabolic traits, behavioural factors – new companies can generate insights that translate across tumour types. Unlike traditional oncology, which often focuses on sequential improvements in a single cancer, resilience-driven research offers multi-cancer applicability and faster routes to proof-of-concept.

The commercial opportunity is equally compelling. Investors who backed precision medicine in its early days remember how a small niche became an unstoppable category. Survival-driven oncology is at a similar inflexion point: scientifically inevitable, but commercially underfunded. The first companies to build datasets, computational models, patient networks, and regulatory pathways around exceptional survival will define the category.

The next generation of oncology breakthroughs will not come from studying averages – they will come from decoding extraordinary survivors, from learning what occasionally happens – but should happen more often. Exceptional survivors are not anomalies. They are biological prototypes. Startups have a chance to turn rare stories into reproducible science and, in doing so, transform survival from an exception to an expectation.

Related articles

• Cure51 joins WIN – how this milestone strengthens global cancer-resilience research
• Cure51’s innovative approach to cancer treatment – exploring their unique TechBio methodology
• Cure51: a radical new approach to beating cancer – the vision shaping Cure51’s long-term impact
• Cure51 to revolutionize cancer treatment – why Cure51 is positioned to transform oncology

More Deep Tech Startup Coverage

• Europes EIC Scaling Club Just Produced Its First Unicorn — And Outperformed Rejected Applicants by 2.3x
• Maisa Hits 400% Growth Building What 95% of Enterprise AI Projects Are Missing: Accountability
• Willo Raises €2.9M Pre-Seed to Scale Alignment-Free Wireless Power
• A Conversation with Tom Henriksson: Exits, AI and Quantum After 2025

Related articles: The Role of Real-World Evidence in Accelerating Drug Development | Cure51 – Ethical Principles in TechBio: Balancing Innovation with Responsibility | French Cure51 Secures €15M Seed Funding to Revolutionize Cancer Treatment with Survivor Research